Current use of pimobendan in canine patients with heart disease.
Adrian Boswood
Index: Vet. Clin. North Am. Small Anim. Pract. 40(4) , 571-80, (2010)
Full Text: HTML
Abstract
Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. The best evidence regarding its efficacy is derived from several clinical studies of dogs with the two most common conditions that result in heart failure: dilated cardiomyopathy (DCM) and degenerative mitral valve disease (DMVD). The main studies addressing the effectiveness of pimobendan in dogs with DCM and DVMD are discussed in this article.
Related Compounds
Related Articles:
Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives.
2010-06-01
[Bioorg. Med. Chem. 18 , 3985-91, (2010)]
Valvular dysplasia and congestive heart failure in a juvenile African penguin (Spheniscus demersus).
2014-12-01
[J. Zoo Wildl. Med. 45(4) , 987-90, (2014)]
2015-06-01
[J. Cardiovasc. Pharmacol. 65(6) , 640-8, (2015)]
A review of the pharmacology and clinical uses of pimobendan.
2012-08-01
[J. Vet. Emerg. Crit. Care (San Antonio.) 22(4) , 398-408, (2012)]
In vitro effect of pimobendan on platelet aggregation in dogs.
2013-03-01
[Am. J. Vet. Res. 74(3) , 403-7, (2013)]